Placebo News and Research

RSS

Acute cannabis intoxication appears to broadly disrupt most of the memory systems

Smoking cannabis can do more than blur memories. It can reshape them.

10 Mar 2026

Daily multivitamin intake linked to slower biological aging in older adults

An analysis led by Mass General Brigham investigators found slower aging in older adults after two years of a daily multivitamin, with greater benefits for those who began the trial with accelerated biological age.

9 Mar 2026

Most weight lost on GLP-1 drugs returns within a year after stopping

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies for effective long-term weight loss.

9 Mar 2026

PET imaging reveals molecular mechanism behind ketamine's antidepressant effects

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies.

6 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

Repurposed kidney drug finerenone shows promise in treating premature ovarian insufficiency

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age.

5 Mar 2026

Novel gene regulation therapy passes key clinical milestone

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet syndrome for whom antiseizure medications are not effective.

4 Mar 2026

Natural fungal supplement strengthens vaccine protection without increasing side effects

Researchers at University California San Diego School of Medicine have found that a natural fungal supplement taken at the time of COVID-19 vaccination reduced short-term vaccine side effects and helped antibodies - the body's natural immune defenders - last longer in people who had not previously been exposed to the virus.

4 Mar 2026

Drinking sparkling water helps gamers stay mentally sharp for hours

Sparkling water may combat cognitive fatigue in gamers, sustaining mental sharpness and executive function during extended esports sessions without stimulants.

4 Mar 2026

Sucrose reduces pain in newborns during hospital needle procedures

A new Cochrane review has found that sucrose can help with pain relief in newborn babies during common hospital procedures, such as venepuncture. This involves drawing blood with a needle, typically for testing.

3 Mar 2026

Chronic back pain linked to heightened sound sensitivity in the brain

People with chronic back pain process everyday sounds differently, and more intensely, than people without pain, according to new research from the University of Colorado Anschutz.

2 Mar 2026

Low‑dose oral lithium may help slow the decline of verbal memory, trial suggests

Lithium-a decades-old treatment for bipolar disorder-may hold potential neuroprotective benefits beyond mood stabilization.

2 Mar 2026

A new standard for preventing post-surgery kidney cancer relapse

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.

1 Mar 2026

Can peanut butter improve mobility after 65?

Research indicates that peanut butter can enhance muscle power in older adults, but its impact on overall physical function and gait speed is limited.

27 Feb 2026

Meningococcal B vaccine fails to prevent gonorrhea, trial shows

Contrary to existing evidence from observational studies, the meningococcal B vaccine (4CMenB) has no effect on preventing the acquisition of gonorrhea, according to the results of the world's largest randomized control trial (RCT) into possible efficacy, conducted by Griffith University's Institute for Biomedicine and Glycomics and the Kirby Institute at UNSW Sydney.

25 Feb 2026

Opioids offer limited short-term relief for acute pain

The world's largest review of opioid pain relievers prescribed for acute pain found these medicines provide only small, short-term relief for some acute conditions and are ineffective for some others.

25 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

Onset of "the munchies" after cannabis use could offer clues to help people with appetite loss

The urgent onset of "the munchies" after cannabis use isn't imaginary – it's a cognitive response that occurs regardless of sex, age, weight or recent food consumption and could offer clues to help people struggling with appetite loss.

19 Feb 2026

Does Ginkgo biloba help dementia? New review examines the evidence

A major Cochrane review examines whether a widely used herbal supplement truly supports cognitive function, revealing modest dementia benefits but limited evidence for prevention or early impairment.

18 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026